Member Article

Manchester-based drug development company Redx launch third subsidiary

Manchester-based Redx, the drug discovery and development company, has announced the launch of its third subsidiary, Redx Immunology Limited (“Redx Immunology”), which will focus on developing new therapies for disorders of the immune system.

Redx Immunology will deliver up to eight new drug development candidates over the near to medium term for progression into clinical trials.

Redx Immunology will operate at Redx’s laboratories at Alderley Park, Cheshire and is being launched using the proceeds from the Company’s recent IPOtogether with the matched funding from the Group’s £4.2 million grant award from the UK Government’s Regional Growth Fund (“RGF”).

Chief executive of Redx Pharma, Dr Neil Murray, said:“Diseases involving the immune system represent some of the most defining public health challenges of the developed world.

“Our new R&D centre for immunology will build on the expertise that we are bringing to bear in the key area of tumour immunology, where we are looking to switch on the body’s immune system to attack cancer cells.

“Our new work in immunology will be focused around creating therapeutics that seek to turn off the immune system and tackle conditions such as inflammation and auto-immune diseases.

“We believe that Redx’s approach and methodology has the potential to make a significant contribution to the industry’s R&D pipeline in the immunology area and will be attractive to large and emerging mid-size pharmaceutical companies as they seek to collaborate with companies such as Redx to develop new therapies.”

This was posted in Bdaily's Members' News section by Sophia Taha .